LBRX LB Pharmaceuticals Inc Common Stock
USHealthcareAs of 2026-07-10 14:00
Why LBRX matters now
LB Pharmaceuticals Inc Common Stock (LBRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $32.70 with -3.10% on the session and $937.6M in market capitalization; recent performance reads 1-month +10.01% and YTD +34.77%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.1M, and EPS of $-0.67. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.0%.
The latest indexable market news headline is "LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.50. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.24
P/S
0.00
EV/EBITDA
-13.91
DCF Value
$9.67
FCF Yield
-6.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-17.7%
ROA
-10.0%
ROIC
-12.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.1M | $-0.67 |
| Q4 2025 | $0.00 | $-11.5M | $-0.45 |
| FY 2025 | $0.00 | $-25.2M | $-1.00 |
| Q3 2025 | $0.00 | $-3.6M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$39.50
Target (Median)
$38.50
Target Range
$36.00 - $45.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.71
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.